Arrowhead Pharmaceuticals (ARWR) Enterprise Value (2010 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 17 years of Enterprise Value data on file, last reported at -$1.8 billion in Q1 2026.

• Quarterly Enterprise Value fell 64.08% year-over-year to -$1.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.8 billion (down 64.08% YoY) and the FY2025 annual result came in at -$882.0 million, down 30.6% from the prior year.
• Enterprise Value eased to -$1.8 billion in Q1 2026, from -$922.3 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$88.2 million in Q3 2022 to a low of -$1.8 billion in Q1 2026.
• A 5-year average of -$613.8 million and a median of -$482.5 million in 2022 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2022 — Enterprise Value surged 71.66% — and 2023, when it slumped 339.76%.
• Tracing ARWR's Enterprise Value over 5 years: stood at -$482.5 million in 2022, then surged by 57.1% to -$207.0 million in 2023, then slumped by 165.4% to -$549.4 million in 2024, then sank by 67.88% to -$922.3 million in 2025, then slumped by 95.07% to -$1.8 billion in 2026.
• The last three Enterprise Value figures came in at -$1.8 billion (Q1 2026), -$922.3 million (Q4 2025), and -$882.0 million (Q3 2025), per Business Quant data.